O	0	9	Celecoxib
O	10	14	anti
O	14	15	-
O	15	24	aromatase
O	25	36	neoadjuvant
O	37	38	(
O	38	42	CAAN
O	42	43	)
O	44	49	trial
O	50	53	for
O	54	61	locally
O	62	70	advanced
O	71	77	breast
O	78	84	cancer
O	84	85	.

O	86	88	To
O	89	97	evaluate
O	98	101	the
O	102	110	efficacy
O	111	114	and
O	115	121	safety
O	122	124	of
O	125	132	combing
O	133	142	aromatase
O	143	152	inhibitor
O	153	154	(
O	154	156	AI
O	156	157	)
O	158	161	and
O	162	176	cyclooxygenase
O	176	177	-
O	177	178	2
O	179	180	(
O	180	183	COX
O	183	184	-
O	184	185	2
O	185	186	)
O	187	196	inhibitor
O	197	210	neoadjuvantly
O	211	213	in
O	214	228	postmenopausal
O	229	237	patients
O	238	242	with
O	243	251	invasive
O	252	259	hormone
O	259	260	-
O	260	269	sensitive
O	270	276	breast
O	277	283	cancer
O	283	284	.

B-total-participants	285	291	Eighty
I-total-participants	291	292	-
I-total-participants	292	295	two
O	296	304	patients
O	305	309	were
O	310	318	randomly
O	319	327	assigned
O	328	330	to
O	331	338	receive
B-intervention	339	349	exemestane
I-intervention	350	354	25mg
I-intervention	355	360	daily
I-intervention	361	364	and
I-intervention	365	374	celecoxib
I-intervention	375	380	400mg
O	381	386	twice
O	387	392	daily
O	393	394	(
O	394	399	group
O	400	401	A
O	401	402	,
O	403	404	n
O	404	405	=
B-intervention-participants	405	407	30
O	407	408	)
O	408	409	,
O	410	420	exemestane
O	421	425	25mg
O	426	431	daily
O	432	433	(
O	433	438	group
O	439	440	B
O	440	441	,
O	442	443	n
O	443	444	=
B-intervention-participants	444	446	24
O	446	447	)
O	448	451	and
B-control	452	461	letrozole
O	462	463	2
O	463	464	.
O	464	467	5mg
O	468	473	daily
O	474	475	(
O	475	480	group
O	481	482	C
O	482	483	,
O	484	485	n
O	485	486	=
B-control-participants	486	488	28
O	488	489	)
O	489	490	.

O	491	494	All
O	495	501	groups
O	502	508	showed
B-outcome	509	517	clinical
I-outcome	518	527	responses
O	528	529	(
B-iv-bin-percent	529	531	58
I-iv-bin-percent	531	532	.
I-iv-bin-percent	532	533	6
I-iv-bin-percent	533	534	%
O	535	538	for
O	539	544	group
O	545	546	A
O	546	547	,
B-iv-bin-percent	548	550	54
I-iv-bin-percent	550	551	.
I-iv-bin-percent	551	552	5
I-iv-bin-percent	552	553	%
O	554	557	for
O	558	563	group
O	564	565	B
O	566	569	and
B-cv-bin-percent	570	572	62
I-cv-bin-percent	572	573	.
I-cv-bin-percent	573	574	0
I-cv-bin-percent	574	575	%
O	576	579	for
O	580	585	group
O	586	587	C
O	587	588	)
O	589	592	and
B-outcome	593	601	decrease
I-outcome	602	604	in
I-outcome	605	610	tumor
I-outcome	611	615	area
O	616	617	(
B-iv-bin-percent	617	619	61
I-iv-bin-percent	619	620	.
I-iv-bin-percent	620	621	8
I-iv-bin-percent	621	622	%
O	623	626	for
O	627	632	group
O	633	634	A
O	634	635	,
B-iv-bin-percent	636	638	58
I-iv-bin-percent	638	639	.
I-iv-bin-percent	639	640	1
I-iv-bin-percent	640	641	%
O	642	645	for
O	646	651	group
O	652	653	B
O	654	657	and
B-cv-bin-percent	658	660	55
I-cv-bin-percent	660	661	.
I-cv-bin-percent	661	662	7
I-cv-bin-percent	662	663	%
O	664	667	for
O	668	673	group
O	674	675	C
O	675	676	)
O	676	677	.

B-iv-bin-abs	678	679	3
O	680	683	out
O	684	686	of
B-intervention-participants	687	688	5
O	689	697	patients
O	698	702	with
B-outcome	703	711	complete
I-outcome	712	720	clinical
I-outcome	721	729	response
O	730	734	were
O	735	743	observed
O	744	748	from
O	749	754	group
O	755	756	A
O	757	760	and
B-cv-bin-abs	761	762	2
O	763	766	out
O	767	769	of
B-control-participants	770	772	69
O	773	781	patients
O	782	790	operated
O	791	795	with
O	796	806	pathologic
O	807	815	complete
O	816	824	response
O	825	829	were
O	830	838	observed
O	839	841	in
O	842	847	group
O	848	849	C
O	849	850	.

O	851	854	The
B-outcome	855	859	mean
I-outcome	860	871	microscopic
I-outcome	872	877	tumor
I-outcome	878	882	size
O	883	886	was
B-iv-cont-mean	887	888	2
I-iv-cont-mean	888	889	.
I-iv-cont-mean	889	891	53
I-iv-cont-mean	892	894	cm
O	895	898	for
O	899	904	group
O	905	906	A
O	906	907	,
B-iv-cont-mean	908	909	3
I-iv-cont-mean	909	910	.
I-iv-cont-mean	910	912	05
I-iv-cont-mean	913	915	cm
O	916	919	for
O	920	925	group
O	926	927	B
O	928	931	and
B-cv-cont-mean	932	933	2
I-cv-cont-mean	933	934	.
I-cv-cont-mean	934	936	10
I-cv-cont-mean	937	939	cm
O	940	943	for
O	944	949	group
O	950	951	C
O	951	952	.

O	953	956	The
O	957	968	differences
O	969	973	were
O	974	978	only
O	979	992	statistically
O	993	1004	significant
O	1005	1009	when
O	1010	1015	group
O	1016	1017	C
O	1018	1021	was
O	1022	1030	compared
O	1031	1035	with
O	1036	1041	group
O	1042	1043	B
O	1044	1045	(
O	1045	1046	P
O	1046	1047	=
O	1047	1048	0
O	1048	1049	.
O	1049	1052	025
O	1052	1053	)
O	1053	1054	.

O	1055	1058	The
B-outcome	1059	1067	toxicity
I-outcome	1068	1076	profiles
O	1077	1082	among
O	1083	1089	groups
O	1090	1094	were
O	1095	1107	satisfactory
O	1107	1108	.

O	1109	1111	AI
O	1112	1114	is
O	1115	1124	effective
O	1125	1127	in
O	1128	1136	treating
O	1137	1143	breast
O	1144	1150	cancer
O	1151	1154	and
O	1155	1158	may
O	1159	1161	be
O	1162	1168	safely
O	1169	1173	used
O	1174	1188	preoperatively
O	1188	1189	.

O	1190	1193	The
O	1194	1202	addition
O	1203	1205	of
O	1206	1209	COX
O	1209	1210	-
O	1210	1211	2
O	1212	1221	inhibitor
O	1222	1225	may
O	1226	1233	provide
O	1234	1244	additional
O	1245	1252	benefit
O	1252	1253	.
